Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23,474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. Among authors: gupta s. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Hoimes CJ, et al. Among authors: gupta s. Future Oncol. 2024 Mar;20(7):351-360. doi: 10.2217/fon-2023-0112. Epub 2023 Nov 23. Future Oncol. 2024. PMID: 37994649 Free PMC article. Review.
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Nizam A, Rader RK, Tzeng A, Wei W, Sheng IY, Martin A, Wee CE, Gilligan TD, Gupta S, Ornstein MC. Nizam A, et al. Among authors: gupta s. Clin Genitourin Cancer. 2024 Apr;22(2):368-379. doi: 10.1016/j.clgc.2023.12.007. Epub 2023 Dec 15. Clin Genitourin Cancer. 2024. PMID: 38245437
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS, Yamamoto Y, Petrylak DP, Sternberg CN, Gupta S, Huang B, Costa N, Laliberte RJ, di Pietro A, Valderrama BP, Powles T. Grivas P, et al. Among authors: gupta s. Eur Urol. 2023 Jul;84(1):95-108. doi: 10.1016/j.eururo.2023.03.030. Epub 2023 Apr 28. Eur Urol. 2023. PMID: 37121850 Free article. Clinical Trial.
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Sridhar SS, Powles T, Climent Durán MÁ, Park SH, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB, Gupta S, Petrylak DP, Bellmunt J, Wang J, Laliberte RJ, di Pietro A, Costa N, Grivas P, Sternberg CN, Loriot Y. Sridhar SS, et al. Among authors: gupta s. Eur Urol. 2024 Feb;85(2):154-163. doi: 10.1016/j.eururo.2023.08.001. Epub 2023 Sep 14. Eur Urol. 2024. PMID: 37714742 Free article. Clinical Trial.
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
Schuster J, Sheng IY, Reddy CA, Khorana AA, Nizam A, Gupta S, Gilligan T, Wee CE, Sussman TA, Bonham A, Maroli K, Martin A, Ornstein MC. Schuster J, et al. Among authors: gupta s. Clin Genitourin Cancer. 2024 Apr;22(2):92-97. doi: 10.1016/j.clgc.2023.09.005. Epub 2023 Oct 5. Clin Genitourin Cancer. 2024. PMID: 37932205
Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis.
Monteiro FSM, Soares A, Mollica V, Leite CA, Carneiro APCD, Rizzo A, Bourlon MT, Sasse AD, Santoni M, Gupta S, Massari F. Monteiro FSM, et al. Among authors: gupta s. Crit Rev Oncol Hematol. 2024 Apr;196:104321. doi: 10.1016/j.critrevonc.2024.104321. Epub 2024 Mar 7. Crit Rev Oncol Hematol. 2024. PMID: 38460929 Review.
Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.
Li R, Naidu S, Fan W, Rose K, Huelster H, Grass GD, Vosoughi A, Dhillon J, Kim Y, Gupta S, Jain RK, Zhang J, Zemp L, Yu A, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Sexton WJ. Li R, et al. Among authors: gupta s. Urol Oncol. 2023 Nov;41(11):457.e17-457.e24. doi: 10.1016/j.urolonc.2023.09.017. Epub 2023 Oct 23. Urol Oncol. 2023. PMID: 37880002
23,474 results
You have reached the last available page of results. Please see the User Guide for more information.